Clinical Trials Logo

Atherosclerosis clinical trials

View clinical trials related to Atherosclerosis.

Filter by:

NCT ID: NCT05813171 Not yet recruiting - Atherosclerosis Clinical Trials

The Effects of Allicor on Patients After Revascularization Treatment During a Year

TEA-PARTY
Start date: April 20, 2023
Phase: Phase 4
Study type: Interventional

A significant challenge in medical care is atherosclerotic occlusion of peripheral arteries, such as lower extremities and brachiocephalic arteries, which can eventually lead to loss of limbs or fatal ischemic strokes. Revascularizing surgical interventions can restore the lumen of the arteries and provide an effective way to treat such patients. However, up to a third of patients need re-intervention or experience cardiovascular complications within a year after surgery. The purpose of this study is to evaluate the effect of adding the natural dietary supplement Allicor to conventional treatment on the incidence of cardiovascular complications and treatment effectiveness 12 months after revascularization. Another valuable area of investigation is the search for predictors of long-term cardiovascular complications after revascularization, which could be markers of inflammation and heteroplasmy levels in the patient's mitochondrial genome.

NCT ID: NCT05796739 Not yet recruiting - Clinical trials for Coronary Atherosclerosis Due to Calcified Coronary Lesion

Routine Versus As-Needed Stress Testing in Asymptomatic Patients With High-Risk Coronary Calcium

SMART-EXAM
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The purpose of the SMART-EXAM (SMart Angioplasty Research Team-Pragmatic Randomized Trial for Comparing Routine versus As-Needed EXercise or Pharmacologic Stress Testing in Asymptomatic Patients with High-Risk Coronary CalciuM) trial is to compare the major adverse cardiovascular events between routine stress testing and as-needed stress testing in asymptomatic patients with high-risk coronary calcium (Agatston Score ≥ 400) without proven ASCVD.

NCT ID: NCT05757505 Not yet recruiting - Clinical trials for Intracranial Atherosclerosis

The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis

Start date: March 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of symptomatic intracranial atherosclerotic stenosis.

NCT ID: NCT05700266 Not yet recruiting - Ischemic Stroke Clinical Trials

Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis

AA-ICAS
Start date: December 30, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary goal of the clinical trial is to test the effect of oral rivaroxaban plus aspirin in patients with recent stroke/ transient ischemic attack (TIA) caused by intracranial artery stenosis. Participants will be divided into 2 groups to receive either oral rivaroxaban plus aspirin or oral clopidogrel plus aspirin. The main question it aims to answer is whether the experimental group (oral rivaroxaban plus aspirin) is superior to the control group ( oral clopidogrel plus aspirin) to lower recurrent stroke/TIA or death in these patients during 1 year of follow-up.

NCT ID: NCT05660798 Not yet recruiting - Clinical trials for Coronary Artery Disease

Effects of Switching From Cigarettes to Tobacco Heating System on Coronary Atherosclerosis Progression

SWITCH
Start date: January 2, 2023
Phase: N/A
Study type: Interventional

Objective: To evaluate the impact of heated versus combustion tobacco products on progression of atherosclerosis in patients with CAD unable(unwilling) to quit smoking. Rationale: Despite the efforts to curb smoking and full awareness of its deleterious health impact, smoking remains a significant contributor to morbidity and mortality. Some health impact of smoking may be improved by other forms of cigarettes than traditional combustion, especially for subjects unwilling or unable to stop smoking. As recently as 2020, one of heated tobacco products (HTP)(IQOS) was FDA Authorized as a 'Reduced Exposure' product. The available evidence to date allows to conclude that the IQOS system heats tobacco but does not burn it, which significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduced body's exposure to harmful or potentially harmful chemicals. There is also evidence indicating lower levels of inflammatory markers and improved vascular function associated with use of heated tobacco products. However, it is unknown whether the reduction in the exposure translates into potential reduction of harm within cardiovascular system, as compared to the traditional (combustion) cigarettes. The evidence is of crucial importance for patients with cardiovascular diseases, medical community, and national health authorities planning evidence based policies regarding HTP/cigarettes.

NCT ID: NCT05593224 Not yet recruiting - Clinical trials for Intracranial Atherosclerosis

The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic Stenosis

Start date: November 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of intracranial atherosclerotic stenosis.

NCT ID: NCT05540223 Not yet recruiting - Clinical trials for Coronary Artery Disease

Safety and Clinical Performance of the DREAMS 3G Resorbable Magnesium Scaffold System

BIOMAG-II
Start date: May 2024
Phase: N/A
Study type: Interventional

The objective of this study is to assess the safety and efficacy of the DREAMS 3G in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to a contemporary drug eluting stent (DES).

NCT ID: NCT05532553 Not yet recruiting - Clinical trials for Atherosclerosis With Diabetes Mellitus and Fatty Liver

Relation Between Carotid Atheroscerosis With DM &Fatty Liver

Start date: September 1, 2022
Phase:
Study type: Observational

To determine the risk of atherosclerosis in NAFLD patients who have T2DM by meauring Carotid intima media thickness (CIMT) using carotid doppler ultrasound.

NCT ID: NCT05478291 Not yet recruiting - Atherosclerosis Clinical Trials

Vitamin D Supplementation on Surrogate Markers of Atherosclerosis

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

For this study, our sample population is individuals with prediabetes, who are at an increased risk for atherosclerosis. In this proposed randomized placebo-controlled prospective trial, we would be enrolling 120 subjects with prediabetes having vitamin D deficiency. These subjects will be randomized into two groups; lifestyle modification counselling along with intervention with either vitamin D supplementation or placebo. Clinical and dietary profiles including sunlight exposure, anthropometry, glycemic and lipid profiles, fasting insulin, adiponectin, body composition (DEXA), skinfolds (4 sites), surrogate markers of atherosclerosis/inflammation (TNF-alpha, hs-CRP, Matrix Metalloproteinase-9, flow-mediated dilatation of brachial artery, pulse wave velocity, and carotid intima-mediated thickness) will be measured at week 0 and week.

NCT ID: NCT05294653 Not yet recruiting - Clinical trials for Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes

Start date: June 1, 2022
Phase:
Study type: Observational

For children and adolescents with diabetes, the pathological process of atherosclerotic cardiovascular disease(ASCVD) can exist in early childhood and progress rapidly to subclinical ASCVD. This study intends to explore the models for the prediction of ASCVD risk in childhood and teen-age onset diabetes with different types.